Developer docs
API playgroundTry for free, no card

Search company profiles

CarboCode

Full company profile

uuid0002fkb

Namestring
CarboCode
Legal namestring
CarboCode S.A.
Websiteurl
carbocode.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CarboCode S.A. is a privately held biotechnology company founded in 2017 and headquartered in Cantanhede, Portugal, with a research center in Konstanz, Germany. The company produces human-identical sphingolipids — including gangliosides (notably GM3 and GD3), glycosphingolipids, and ceramides — by integrating biocatalysis, fermentation, protein and metabolic engineering, and chemistry into a single platform that, according to the company, can be industrialized at food-industry cost levels. CarboCode's core scientific team and co-founders developed their expertise at Glycom A/S, where they participated in commercializing the first human milk oligosaccharides.

The company's commercial focus is B2B ingredient supply rather than consumer products. Its primary commercial application is supplying human milk gangliosides and glycosphingolipids to infant formula manufacturers, with Danone, Nestlé, Abbott, and Mead Johnson cited as customers. Secondary applications target ceramides for skin care and dermatology, and gangliosides for adult cognitive and gastrointestinal health, though these remain less commercially advanced. Distribution is entirely export-oriented via direct enterprise sales to global formula brands and is supported by scientific conference engagement, including presentations at the ESPGHAN annual meeting on the infant gut microbiome.

CarboCode is currently in a pre-industrial-scale phase. The company has 60+ employees of roughly 10 nationalities, is preparing HACCP and ISO 22000 certification at its Cantanhede Technology Transfer Center, and is building a new industrial factory at the BioCant Park complex designed for up to 100 tons of gangliosides per year. It raised a €15 million Series C led by Iberis Capital in late 2024 and is targeting regulatory approvals in the EU and US by 2027 and China by 2028, with a stated objective of exceeding €100 million in annual turnover by 2029. CEO Jorge Santos was appointed in August 2024 to lead the industrialization phase.

Short descriptiontext

CarboCode is a Portugal-based biotech that produces human-identical sphingolipids (gangliosides, glycosphingolipids, ceramides) at commercial scale via an integrated biocatalysis and fermentation platform, supplying these ingredients on a B2B basis to global infant formula manufacturers including Danone, Nestlé, Abbott, and Mead Johnson.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCantanhede, Portugal
HQ citystring
Cantanhede
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human sphingolipid production, ganglioside ingredients, infant formula ingredients, bioactive lipid manufacturing, ceramide skincare ingredients
Industry3 codes
PRIMARYAFAJALAM
Lipid-Based Emulsions & Encapsulated Oils (Spray-Dried Oils, Microencapsulation)
Agriculture & Food Production/Food Ingredients & Additives/Fats & Oils Ingredients (Edible Oils, Specialty Fats, Lipid Systems)
SECONDARYAFAJAKAL
Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAOAL
Fats, Oils & Lipid Ingredients (Specialty Oils, MCTs, Structured Lipids)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Bioactive Lipid Ingredients
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1B2B Ingredient Sales
TypeOne Time License
Description

CarboCode operates as a B2B ingredient supplier, selling human-identical sphingolipids and gangliosides to major infant formula manufacturers. The company projects annual turnover exceeding €100M by 2029, with all production dedicated to exports. Revenue is generated through ingredient sales contracts with global formula brands.

carbocode.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CarboCode develops and manufactures human-identical sphingolipids—gangliosides (including GM3 and GD3), glycosphingolipids, and ceramides—at industrial scale using an integrated proprietary platform combining biocatalysis, fermentation, protein and metabolic engineering, and chemistry. The company sells these bioactive lipid ingredients on a B2B basis to global infant formula manufacturers (Danone, Nestlé, Abbott, Mead Johnson) and to skincare and adult nutrition customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Projected annual turnover exceeding €100M by 2029
+2 more records
Product overview1 text field

CarboCode is a biotechnology company that produces human-identical sphingolipids (gangliosides, glycosphingolipids, and ceramides) at commercial scale. The company's product portfolio centers on three core bioactive lipid categories: Human Milk Gangliosides (GM3 and GD3) for infant nutrition, Glycosphingolipids serving multiple applications including infant nutrition, skin care, and adult nutrition/cognitive health, and Ceramides specifically for skin care. CarboCode operates as a B2B supplier, providing these ingredients to global formula brands and cosmetics manufacturers rather than selling directly to consumers.

Product and service3 records
1Human Milk Gangliosides (GM3 and GD3)
CategoryInfant Nutrition Ingredients
Description

Human-identical GM3 and GD3 gangliosides produced at commercial scale, used as bioactive lipid ingredients that bring infant formula closer to mother's milk by providing components essential to the development of babies. Intended for B2B sale to global infant formula manufacturers.

2Glycosphingolipids
CategorySpecialty Bioactive Lipid Ingredients
Description

Human-identical glycosphingolipids produced at commercial scale for application across infant nutrition, skin care, and adult nutrition/cognitive health markets. Sold on a B2B basis to global formula brands and cosmetics manufacturers.

3Ceramides
CategorySkincare Ingredients
Description

Human-identical ceramides for skin care applications, positioned as essential to a healthy skin barrier and capable of targeting major skin disorders. Sold as B2B ingredients to skincare, cosmetics, and dermatology manufacturers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Division of BASF supplying vitamins, carotenoids, omega-3 lipids and other nutritional ingredients to global food customers. Broad incumbent in nutritional lipid ingredients with deep FMCG relationships relevant to CarboCode's go-to-market.

TypeEmerging player
Description

Family-owned global yeast and fermentation specialist expanding into human milk oligosaccharides and other precision fermentation ingredients. Comparable fermentation platform and ambition to enter B2B bioactive ingredient markets.

TypeBroad incumbent
Description

Global bioscience ingredient supplier with growing HMOs and microbiome offerings for infant formula and nutrition. Much larger scale and broader portfolio, but competes in the same B2B bioactive-ingredient category as CarboCode.

TypeBroad incumbent
Description

Global taste and nutrition ingredients company with a dedicated infant nutrition portfolio. Comparable B2B customer set and ingredient-supply business model, though broader and not sphingolipid-focused.

TypeBroad incumbent
Description

Specialty chemicals company with a nutrition & care division producing lipid-based and biotech ingredients for food and pharma. Relevant peer for lipid chemistry capabilities and regulated ingredient supply to global FMCG customers.

TypeBroad incumbent
Description

Global nutrition, health and ingredients major with HMO and lipid-based ingredients marketed to the same tier-1 infant formula customers as CarboCode. Represents both a partner/distribution channel and the most likely in-house competitor.

TypeDirect peer
Description

Belgian biotech specializing in human milk oligosaccharides and specialty carbohydrates via biocatalysis and fermentation. Closely comparable production platform and target end-markets in infant nutrition, with overlapping glycochemistry expertise.

TypeBroad incumbent
Description

Large nutrition and biosciences ingredient platform resulting from the DuPont Nutrition & Biosciences merger with IFF; supplies HMOs and other infant formula ingredients globally. Overlaps with CarboCode on customer set and category.

TypeDirect peer
Description

Pioneer in industrial production of human milk oligosaccharides (HMOs) for infant formula; CarboCode's founders helped industrialize HMOs at Glycom before founding CarboCode to apply analogous glycobiotech to sphingolipids. Most directly comparable technology and customer base.

TypeBroad incumbent
Description

Major agricultural and food ingredient supplier with a growing health and nutrition portfolio including specialty lipids and fermentation-derived ingredients. Comparable B2B ingredient supply model serving global food and nutrition brands.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CarboCode

Specialty Bioactive Lipid Ingredientscarbocode.com

CarboCode is a Portugal-based biotech that produces human-identical sphingolipids (gangliosides, glycosphingolipids, ceramides) at commercial scale via an integrated biocatalysis and fermentation platform, supplying these ingredients on a B2B basis to global infant formula manufacturers including Danone, Nestlé, Abbott, and Mead Johnson.

What CarboCode does

CarboCode S.A. is a privately held biotechnology company founded in 2017 and headquartered in Cantanhede, Portugal, with a research center in Konstanz, Germany. The company produces human-identical sphingolipids — including gangliosides (notably GM3 and GD3), glycosphingolipids, and ceramides — by integrating biocatalysis, fermentation, protein and metabolic engineering, and chemistry into a single platform that, according to the company, can be industrialized at food-industry cost levels. CarboCode's core scientific team and co-founders developed their expertise at Glycom A/S, where they participated in commercializing the first human milk oligosaccharides.

The company's commercial focus is B2B ingredient supply rather than consumer products. Its primary commercial application is supplying human milk gangliosides and glycosphingolipids to infant formula manufacturers, with Danone, Nestlé, Abbott, and Mead Johnson cited as customers. Secondary applications target ceramides for skin care and dermatology, and gangliosides for adult cognitive and gastrointestinal health, though these remain less commercially advanced. Distribution is entirely export-oriented via direct enterprise sales to global formula brands and is supported by scientific conference engagement, including presentations at the ESPGHAN annual meeting on the infant gut microbiome.

CarboCode is currently in a pre-industrial-scale phase. The company has 60+ employees of roughly 10 nationalities, is preparing HACCP and ISO 22000 certification at its Cantanhede Technology Transfer Center, and is building a new industrial factory at the BioCant Park complex designed for up to 100 tons of gangliosides per year. It raised a €15 million Series C led by Iberis Capital in late 2024 and is targeting regulatory approvals in the EU and US by 2027 and China by 2028, with a stated objective of exceeding €100 million in annual turnover by 2029. CEO Jorge Santos was appointed in August 2024 to lead the industrialization phase.

CarboCode firmographics

Firmographics
Name
CarboCode
Legal name
CarboCode S.A.
Website
https://carbocode.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
CarboCode is a Portugal-based biotech that produces human-identical sphingolipids (gangliosides, glycosphingolipids, ceramides) at commercial scale via an integrated biocatalysis and fermentation platform, supplying these ingredients on a B2B basis to global infant formula manufacturers including Danone, Nestlé, Abbott, and Mead Johnson.
Ownership category
akta.pro rank

CarboCode industry classification

Industry
Product category
Specialty Bioactive Lipid Ingredients
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYAFAJALAM
Lipid-Based Emulsions & Encapsulated Oils (Spray-Dried Oils, Microencapsulation)
Agriculture & Food Production/Food Ingredients & Additives/Fats & Oils Ingredients (Edible Oils, Specialty Fats, Lipid Systems)
SECONDARYAFAJAKAL
Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAOAL
Fats, Oils & Lipid Ingredients (Specialty Oils, MCTs, Structured Lipids)

Keywords

  • Human sphingolipid production
  • Ganglioside ingredients
  • Infant formula ingredients
  • Bioactive lipid manufacturing
  • Ceramide skincare ingredients

Where CarboCode is headquartered

Location

Headquarters

HQ city
Cantanhede
HQ country
Portugal
HQ region
Europe

Offices2 records

Markets served

CarboCode business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations

Revenue model

  1. B2B Ingredient Sales: CarboCode operates as a B2B ingredient supplier, selling human-identical sphingolipids and gangliosides to major infant formula manufacturers. The company projects annual turnover exceeding €100M by 2029, with all production dedicated to exports. Revenue is generated through ingredient sales contracts with global formula brands.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

CarboCode product offering

Product offering

Core offering

CarboCode develops and manufactures human-identical sphingolipids—gangliosides (including GM3 and GD3), glycosphingolipids, and ceramides—at industrial scale using an integrated proprietary platform combining biocatalysis, fermentation, protein and metabolic engineering, and chemistry. The company sells these bioactive lipid ingredients on a B2B basis to global infant formula manufacturers (Danone, Nestlé, Abbott, Mead Johnson) and to skincare and adult nutrition customers.

Product overview

CarboCode is a biotechnology company that produces human-identical sphingolipids (gangliosides, glycosphingolipids, and ceramides) at commercial scale. The company's product portfolio centers on three core bioactive lipid categories: Human Milk Gangliosides (GM3 and GD3) for infant nutrition, Glycosphingolipids serving multiple applications including infant nutrition, skin care, and adult nutrition/cognitive health, and Ceramides specifically for skin care. CarboCode operates as a B2B supplier, providing these ingredients to global formula brands and cosmetics manufacturers rather than selling directly to consumers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human Milk Gangliosides (GM3 and GD3) Human-identical GM3 and GD3 gangliosides produced at commercial scale, used as bioactive lipid ingredients that bring infant formula closer to mother's milk by providing components essential to the development of babies. Intended for B2B sale to global infant formula manufacturers.
  • Glycosphingolipids Human-identical glycosphingolipids produced at commercial scale for application across infant nutrition, skin care, and adult nutrition/cognitive health markets. Sold on a B2B basis to global formula brands and cosmetics manufacturers.
  • Ceramides Human-identical ceramides for skin care applications, positioned as essential to a healthy skin barrier and capable of targeting major skin disorders. Sold as B2B ingredients to skincare, cosmetics, and dermatology manufacturers.

Quantifiable outcome

  • Projected annual turnover exceeding €100M by 2029
  • +2 more outcomes

Companies that use CarboCode

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

CarboCode technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CarboCode partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

CarboCode competitors and assessment

Company assessment

Broad incumbents

  • BASF Nutrition & Health: Division of BASF supplying vitamins, carotenoids, omega-3 lipids and other nutritional ingredients to global food customers. Broad incumbent in nutritional lipid ingredients with deep FMCG relationships relevant to CarboCode's go-to-market.
  • Novonesis (formerly Chr. Hansen): Global bioscience ingredient supplier with growing HMOs and microbiome offerings for infant formula and nutrition. Much larger scale and broader portfolio, but competes in the same B2B bioactive-ingredient category as CarboCode.
  • Kerry Group: Global taste and nutrition ingredients company with a dedicated infant nutrition portfolio. Comparable B2B customer set and ingredient-supply business model, though broader and not sphingolipid-focused.
  • Evonik: Specialty chemicals company with a nutrition & care division producing lipid-based and biotech ingredients for food and pharma. Relevant peer for lipid chemistry capabilities and regulated ingredient supply to global FMCG customers.
  • dsm-firmenich: Global nutrition, health and ingredients major with HMO and lipid-based ingredients marketed to the same tier-1 infant formula customers as CarboCode. Represents both a partner/distribution channel and the most likely in-house competitor.
  • IFF Health & Biosciences (DuPont N&B legacy): Large nutrition and biosciences ingredient platform resulting from the DuPont Nutrition & Biosciences merger with IFF; supplies HMOs and other infant formula ingredients globally. Overlaps with CarboCode on customer set and category.
  • Cargill Health & Nutrition: Major agricultural and food ingredient supplier with a growing health and nutrition portfolio including specialty lipids and fermentation-derived ingredients. Comparable B2B ingredient supply model serving global food and nutrition brands.

Emerging players

  • Lesaffre: Family-owned global yeast and fermentation specialist expanding into human milk oligosaccharides and other precision fermentation ingredients. Comparable fermentation platform and ambition to enter B2B bioactive ingredient markets.

Direct peers

  • Inbiose: Belgian biotech specializing in human milk oligosaccharides and specialty carbohydrates via biocatalysis and fermentation. Closely comparable production platform and target end-markets in infant nutrition, with overlapping glycochemistry expertise.
  • Glycom A/S (now part of dsm-firmenich): Pioneer in industrial production of human milk oligosaccharides (HMOs) for infant formula; CarboCode's founders helped industrialize HMOs at Glycom before founding CarboCode to apply analogous glycobiotech to sphingolipids. Most directly comparable technology and customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

CarboCode social profiles

Digital presence

CarboCode compliance and trust

Trust signal

Compliance2 records

CarboCode financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CarboCode leadership team

Management profile

Number of profiles

Profiles3 records

CarboCode funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CarboCode M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CarboCode

What does CarboCode do?

CarboCode develops and manufactures human-identical sphingolipids—gangliosides (including GM3 and GD3), glycosphingolipids, and ceramides—at industrial scale using an integrated proprietary platform combining biocatalysis, fermentation, protein and metabolic engineering, and chemistry. The company sells these bioactive lipid ingredients on a B2B basis to global infant formula manufacturers (Danone, Nestlé, Abbott, Mead Johnson) and to skincare and adult nutrition customers.

Is CarboCode a public or private company?

CarboCode is a private company. It is classified as venture growth investor backed and is currently operating.

When was CarboCode founded?

CarboCode was founded in 2017. It employs 51 to 100 people.

Where is CarboCode based?

CarboCode is headquartered in Cantanhede, Portugal, in the Europe region.

How does CarboCode make money?

One revenue line is on record: B2B Ingredient Sales.

Who are CarboCode's main competitors?

Broad incumbents on record are BASF Nutrition & Health, Novonesis (formerly Chr. Hansen), Kerry Group, Evonik, dsm-firmenich, IFF Health & Biosciences (DuPont N&B legacy) and Cargill Health & Nutrition. Lesaffre is listed as an emerging player. Direct peers are Inbiose and Glycom A/S (now part of dsm-firmenich).

Does CarboCode have an API?

No public API is recorded for CarboCode.

What industry is CarboCode in?

CarboCode's product category is Specialty Bioactive Lipid Ingredients. Its primary akta.pro industry code is AFAJALAM, Lipid-Based Emulsions & Encapsulated Oils (Spray-Dried Oils, Microencapsulation), with a secondary code of AFAJAKAL, Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried). Its NAICS code is 325414 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechStartupsTop Startup and Tech Funding News – November 11, 2025On November 11, 2025, multiple startups announced funding rounds collectively exceeding $300 million across AI, biotech, fintech, and ESG sectors. Notable deals include Wonderful's $100 million Series A (valued at $700 million) for multilingual enterprise AI agents, myTomorrows' $29 million for its patient access platform to experimental therapies, and CarboCode's €15 million Series C for human-identical milk lipids targeting infant nutrition and neurodegenerative diseases. The funding activity, spanning companies headquartered in Amsterdam, Portugal, Singapore, and Seattle, reflects continued investor confidence in AI automation and health-tech innovation.TechStartupsPortuguese biotech startup CarboCode raises €15M to develop human-identical milk lipids that could aid in fighting Alzheimer’s and Parkinson’sPortuguese biotech startup CarboCode has raised €15 million in Series C funding to develop and scale production of human-identical milk lipids, known as gangliosides, aimed at improving infant formulas and addressing neurodegenerative diseases. The company plans to achieve regulatory approvals in Europe and the US by 2026 and expand into China's market by 2028, with production reaching 100 tons annually by 2029.ProteinproductiontechnologyCarboCode raises €15 million to advance production of human-identical gangliosidesCarboCode, a biotechnology company based in Cantanhede, Portugal, has secured €15 million in a Series C funding round led by Iberis Capital to scale up production of human-identical gangliosides and glycosphingolipids for infant nutrition, dermatology, and cognitive health applications. The company is building its first industrial-scale factory at Biocant Park capable of producing up to 100 tons annually, with regulatory approval targets set for the EU and USA by 2027 and China by 2028. Operating as a B2B supplier to major infant nutrition companies, CarboCode projects annual turnover exceeding €100 million by 2029, with all production dedicated to exports.